Niraparib and Abiraterone Acetate (Akeega)

Abstract

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses niraparib and abiraterone acetate (Akeega), 100 mg/500 mg, 50 mg/500 mg, filmcoated tablets administered orally. Indication : For the treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated.